Charles Darwin University

CDU eSpace
Institutional Repository

CDU Staff and Student only

Is amlodipine the best initial monotherapy for hypertension?

Doggrell, SA (2006). Is amlodipine the best initial monotherapy for hypertension?. Expert Opinion on Pharmacotherapy,7(6):829-832.

Document type: Journal Article
Citation counts: Scopus Citation Count Cited 2 times in Scopus Article | Citations

Google Scholar Search Google Scholar

Title Is amlodipine the best initial monotherapy for hypertension?
Author Doggrell, SA
Journal Name Expert Opinion on Pharmacotherapy
Publication Date 2006
Volume Number 7
Issue Number 6
ISSN 1465-6566   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-33645807356
Start Page 829
End Page 832
Total Pages 4
Publisher Informa Healthcare
HERDC Category C1 - Journal Article (DEST)
Abstract Hypertension is the principle cause of stroke, and leads to coronary artery disease with myocardial infarction and sudden cardiac death. The ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm) trial has recently shown that an amlodipine-based regimen (with perindopril and doxazosin added as required) has greater benefits than an atenolol-based regimen (with bendroflumethiazide and doxazosin). Thus, with the amlodipine-based regimen there was less nonfatal myocardial infarction and fatal heart disease, total cardiovascular events and procedures, cardiovascular mortality, fatal and nonfatal stroke, unstable angina, peripheral arterial disease, development of diabetes and renal impairment. Thus, the amlodipine-based regimen used in ASCOT-BPLA should be preferred to the atenolol-based regimen.
Keywords amlodipine
clinical trial
calcium-channel blocker
arm ascot-bpla
cardiovascular events
DOI   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
Version Filter Type
Access Statistics: 146 Abstract Views  -  Detailed Statistics
Created: Wed, 28 Nov 2007, 14:16:08 CST